News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed
The offering in Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200...
Arcoma: Omsättningen ökar 36%: fortsatta resultatförbättringar:
Arcomas kvartalsrapport för fjärde kvartalet 2018 – bokslutskommuniké – finns att läsa här Press inquiries should be adressed to:
Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm
Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the “Offering”). The Company’s Board of Directors also intend to apply for...
Sunstone announce new corporate structure and brand names
Sunstone Capital today announce that the two investment arms of Sunstone – Life Science Ventures and Technology Ventures – in the future will operate under the names Sunstone Life Science Ventures ( https://sunstone.eu ) and Heartcore Capital, respectively....
Sunstone Life Science Ventures Fund IV announces first close
Sunstone Life Science Ventures today announced the first closing of its Sunstone Life Science Ventures Fund IV (“Sunstone LSV IV”) at €80 million. The investment strategy of the new fund is a continuation of Sunstone’s successful strategy of investing in novel...